Huaren Pharmaceutical Co Ltd (300110) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Huaren Pharmaceutical Co Ltd (300110) has a cash flow conversion efficiency ratio of 0.061x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥86.78 Million ≈ $12.70 Million USD) by net assets (CN¥1.43 Billion ≈ $208.65 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 300110 net asset quality score to measure how much of total assets are equity-financed.
Huaren Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Huaren Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Huaren Pharmaceutical Co Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Huaren Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Huaren Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Central Emporium Group Stocks Co Ltd
SHG:600280
|
0.252x |
|
EUROKAI GmbH & Co. KGaA
F:EUK3
|
0.017x |
|
Hunan Huamin Holdings Co Ltd
SHE:300345
|
-0.046x |
|
Consolidated Water Co Ltd
NASDAQ:CWCO
|
0.068x |
|
Stenhus Fastigheter I Norden AB
ST:SFAST
|
0.021x |
|
Shenzhen Jinxinnong Feed Co Ltd
SHE:002548
|
-0.071x |
|
Nanjing Well Pharmaceutical Co Ltd
SHG:603351
|
0.039x |
|
LandOcean Energy Services Co
SHE:300157
|
0.007x |
Annual Cash Flow Conversion Efficiency for Huaren Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Huaren Pharmaceutical Co Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Huaren Pharmaceutical Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥909.06 Million ≈ $133.02 Million |
CN¥390.23 Million ≈ $57.10 Million |
0.429x | +82.96% |
| 2024-12-31 | CN¥1.37 Billion ≈ $201.05 Million |
CN¥322.36 Million ≈ $47.17 Million |
0.235x | +112.36% |
| 2023-12-31 | CN¥2.77 Billion ≈ $404.75 Million |
CN¥305.60 Million ≈ $44.72 Million |
0.110x | +31.77% |
| 2022-12-31 | CN¥2.60 Billion ≈ $380.43 Million |
CN¥217.98 Million ≈ $31.90 Million |
0.084x | +135.41% |
| 2021-12-31 | CN¥2.44 Billion ≈ $357.55 Million |
CN¥-578.52 Million ≈ $-84.66 Million |
-0.237x | -5034.78% |
| 2020-12-31 | CN¥2.33 Billion ≈ $340.88 Million |
CN¥-10.74 Million ≈ $-1.57 Million |
-0.005x | -103.35% |
| 2019-12-31 | CN¥2.25 Billion ≈ $329.02 Million |
CN¥309.33 Million ≈ $45.26 Million |
0.138x | +21.89% |
| 2018-12-31 | CN¥2.25 Billion ≈ $329.72 Million |
CN¥254.32 Million ≈ $37.21 Million |
0.113x | -17.22% |
| 2017-12-31 | CN¥1.55 Billion ≈ $226.55 Million |
CN¥211.08 Million ≈ $30.89 Million |
0.136x | +14.53% |
| 2016-12-31 | CN¥1.53 Billion ≈ $223.29 Million |
CN¥181.65 Million ≈ $26.58 Million |
0.119x | +813.41% |
| 2015-12-31 | CN¥1.44 Billion ≈ $210.71 Million |
CN¥18.77 Million ≈ $2.75 Million |
0.013x | -70.59% |
| 2014-12-31 | CN¥1.48 Billion ≈ $216.53 Million |
CN¥65.56 Million ≈ $9.59 Million |
0.044x | +62.55% |
| 2013-12-31 | CN¥1.46 Billion ≈ $213.55 Million |
CN¥39.78 Million ≈ $5.82 Million |
0.027x | -63.29% |
| 2012-12-31 | CN¥1.34 Billion ≈ $195.97 Million |
CN¥99.44 Million ≈ $14.55 Million |
0.074x | +48.64% |
| 2011-12-31 | CN¥1.19 Billion ≈ $174.38 Million |
CN¥59.53 Million ≈ $8.71 Million |
0.050x | -28.93% |
| 2010-12-31 | CN¥1.10 Billion ≈ $161.57 Million |
CN¥77.61 Million ≈ $11.36 Million |
0.070x | -42.90% |
| 2009-12-31 | CN¥313.80 Million ≈ $45.92 Million |
CN¥38.63 Million ≈ $5.65 Million |
0.123x | -52.47% |
| 2008-12-31 | CN¥221.03 Million ≈ $32.34 Million |
CN¥57.24 Million ≈ $8.38 Million |
0.259x | +524.40% |
| 2007-12-31 | CN¥184.68 Million ≈ $27.02 Million |
CN¥7.66 Million ≈ $1.12 Million |
0.041x | -- |
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more